Innovations in medicine, such as new therapies and personalised medicine, are frequently noted as reasons for success in the pharmaceutical industry; however, behind every successful pharmaceutical product launch lies a wide-ranging set of interconnected activities, processes, and strategies, which are often not recognised when looking at successful pharmaceuticals. The pharmaceutical industry is a very complex environment comprised of many companies developed to solve operational/regulatory/logistical challenges in bringing new and/or improved drugs to market through the various phases of drug development (i.e. discovery, preclinical, etc.), commercial launch, and subsequent phases of market lifecycles.
The difference between the successful and failing pharmaceutical companies is not just the innovative products created, but the orchestration of the manufacturers’ ability to synchronise manufacturing, licensing, and clinical trial supply chains, making the ability to orchestrate those supply chains a significant competitive advantage.
This blog will explore ways that modern pharmaceutical companies are changing their approach to transforming their supply chain ecosystem by using contract manufacturing consultants, optimising comparator sourcing for clinical trials, and utilising the strategic benefits of pharmaceutical companies with pharma contract companies. Not only will these processes increase production efficiencies, but they will also help build a more resilient and innovative ecosystem for the future.
The New Pharma Reality: Complexity Meets Opportunity
The pharmaceutical sector right now is more dynamic than ever before. Increased regulatory scrutiny, increased R&D costs, and globalisation of supply chains are resulting in both challenges and opportunities for companies.
Companies no longer exist in isolation from each other. Rather, they exist within an interconnected ecosystem where:
- Manufacturing is often outsourced across continents
- Clinical trials are conducted in multiple locations
- Licensing agreements govern how quickly a company can access the market
- Supply chains will need to remain resilient against geopolitical and economic disruption
Why Strategic Guidance is more Important than Ever
A contract manufacturing consultant has become much more than a simple support function for a company; they have become a strategic partner who is integrated into companies’ decision-making processes.
A contract manufacturer consultant provides:
- Unique insight into the global manufacturing network
- Expertise in regional regulatory compliance
- Insight into cost-optimising and risk-mitigating strategies
- Identified and verified pharma contract companies
Instead of simply locating a contract manufacturer for companies, they are developing a long-term strategy to manufacture products.
The Hidden Challenges in Clinical Trial Supply Chains
Pharmaceutical innovation is based on clinical trials. Comparator sourcing is one of the most overlooked factors in clinical trials.
Comparators are drugs used as benchmarks in a study. They must meet strict criteria:
- Authenticity and traceability
- Meeting regulatory requirements for all regions of the world
- Consistent supply and consistent quality
- Proper storage and logistical requirements
The consequence of failing to obtain comparators can be delays in trials, higher costs, and possibly invalid results.
Comparator Sourcing: Reimagined Tactically & Strategically
Traditionally, comparator sourcing was treated like any other procurement activity; now it’s considered to be a strategic function.
Today’s methodologies for comparator sourcing for clinical trials include:
1. Early Integration of Planning
Sourcing comparators should begin as part of trial design, rather than after, to ensure the comparator aligns with protocol requirements and regulatory expectations.
2. Supply Networks Globally
Access to authorised distributors and manufacturers anywhere in the world will mitigate risk and ensure that you will not run out of comparators.
3. Future Predictive Demand
Using predictive analytics will help determine future demand, thereby preventing shortages.
4. Compliance Driven Processes
Compliance with Good Distribution Practices (GDP) and all applicable regulatory frameworks; this is of paramount importance to all individuals engaged in comparator sourcing.
The Expanding Role of Pharma Contract Companies
Pharmaceutical contracting firms have transformed into much more than just the traditional roles they used to play; they provide innovative solutions and support by:
- Providing the full service from start to finish on developing and manufacturing pharmaceuticals.
- Specialised service with unique capabilities in specific therapeutic areas.
- Offering scaling options to increase manufacturing capacity.
- Providing regulatory support and documentation for pharmaceutical licensing.
Together with Pharmaceutical Licensing services, these organisations create new ways of getting into the global marketplace.
Pharma Licensing: The Gateway to Global Expansion
Pharmaceutical licensing offers organisations the chance to enter into new markets, which are among the largest opportunities for growth in the pharmaceutical industry, as well as being a major challenge.
A strong, productive pharma licensing service will ensure the pharmaceutical company has access to the following:
- Market access experience.
- Knowledge of pathways required for regulatory approvals.
- Ability to identify a partner based on the country of interest.
- Assisting with Intellectual Property management when necessary.
Pharmaceutical Licensing has evolved as not just a means of distribution; it is now about strategically placing products within the competitive marketplace.
The Synergy of Manufacturing and Licensing
The real strength can be found through integrating the Pharmaceutical Contract Manufacturer and the Pharmaceutical Licensing Service strategy.
By aligning these two entities, a company will benefit by having:
- Faster time to market.
- Lower capital investments required.
- Access to local manufacturers.
- Better regulatory success rates.
This synergy allows companies to expand on a worldwide basis without overextending resources.
Building a Resilient Pharma Ecosystem
Pharmaceutical companies have made resiliency their number one goal, as pandemics and geopolitical tensions have disrupted supply chains.
There are four key components to building a resilient ecosystem:
1. Diversifying Your Manufacturing Network
By working with multiple locations and suppliers, you can reduce your risk of being affected by disruptions in any one area.
2. Forming Strategic Partnerships
Partnering with contract pharmaceutical companies and consultants that you know and trust can help to improve your resiliency.
3. Embracing Digital Transformation
Using technology to give you real-time visibility into your supply chain and help you make informed decisions.
4. Having Regulatory Agility
Being able to adapt rapidly to changes in compliance regulations.
Digital Transformation: The New Game-Changer
All aspects of the pharmaceutical supply chain are being impacted by the digital world.
From manufacturing and sourcing, digital helps to provide:
- Real-time visibility into your supply chain
- Data-driven decision making
- Improved quality control
- Predictive risk management
Digital platforms provide comparators for the sourcing of drugs in clinical trials by allowing you to see where the drug was produced and the quality control that was performed on it, thus supporting your ability to comply with regulatory requirements.
Risk Management in a Volatile World
In today’s world of volatility, risk is a fact of life, but it can be managed strategically.
Risks include:
- Disrupted supply chains
- Increased regulatory burden
- Inconsistent quality
- Loss of brand value
A contract manufacturing consultant can play an important role in identifying and reducing your risks.
Cost Optimisation Without Compromise
Pharma companies are constantly challenged with balancing their costs with their quality. Three strategies are being used by them to achieve balance:
- Using economies of scale through pharmaceutical contract companies
- Improving their sourcing strategies
- Reducing waste and improving processes
- Using licensing agreements to help reduce costs associated with entering new markets
The ultimate goal in maintaining balance is not only cost savings but also to ensure that maximum value is generated from manufacturing in the pharmaceutical industry.
The Human Factor: Expertise is Key to Success
In addition to technology and strategy, the human element is paramount in producing successful outcomes for the pharmaceutical industry. The following components are necessary for success:
- Consultants with experience in pharmaceutical production
- Reliable manufacturing partners
- Professionals with regulatory knowledge
- Knowledgeable individuals in supply-chain management
These types of collaborations between the above entities make up a complete ecosystem that can tackle the complexities of the pharmaceutical manufacturing environment.
Sustainability in Pharmaceutical Operations
Sustainability has gone from being an afterthought to being a primary reason to conduct business. Today’s practices utilised by the pharmaceutical industry include:
- Environmentally friendly manufacturing process
- Environmentally conscious sourcing models
- Waste minimization
- Energy-efficient processes
Pharmaceutical contract companies are a driving force behind creating sustainable practices for the pharmaceutical industry.
Final Thoughts: From Complex to Clarity
Although the pharmaceutical world looks complex and multifaceted, underneath that complexity lies significant potential for change and growth.
Pharmaceutical companies can create innovative products faster than ever by doing things differently from how they have traditionally done. By moving to a more integrated, forward-thinking model:
- Accelerate innovation cycles
- Reduce the risk of failure (both operationally and legally/regulatory)
- Enter and grow in global markets without difficulty
- Achieve improved patient outcomes through improved efficiency and quality of care
Today’s process from the discovery of a molecule until it reaches consumers is no longer a linear one; rather, it is a continuous, divisible process that requires precise coordination, strategic foresight, and nimble execution at all points in time along the continuum.